Literature DB >> 25175726

Severe cutaneous adverse reaction associated with vemurafenib: DRESS, AGEP or overlap reaction?

A Gey1, B Milpied1, C Dutriaux1, C Mateus2, C Robert2, G Perro3, A Taieb1, K Ezzedine1, T Jouary1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25175726     DOI： 10.1111/jdv.12685

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN： 0926-9959            Impact factor:   6.166


× No keyword cloud information.
  8 in total

1.  Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma.

Authors:  N Kramkimel; A Thomas-Schoemann; L Sakji; Jl Golmard; G Noe; E Regnier-Rosencher; N Chapuis; E Maubec; M Vidal; Mf Avril; F Goldwasser; L Mortier; N Dupin; B Blanchet
Journal:  Target Oncol       Date:  2016-02       Impact factor: 4.493

2.  Stevens-Johnson Syndrome and Severe Anaemia: A Case of Toxicity Induced by Vemurafenib plus Cobimetinib following Pembrolizumab for Metastatic Melanoma.

Authors:  Tanja Batinac; Nika Hlača; Luka Simetić; Frane Valković; Sandra Peternel; Larisa Prpić-Massari
Journal:  Acta Derm Venereol       Date:  2022-02-22       Impact factor: 3.875

3.  Rapid recovery of postnivolumab vemurafenib-induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome after tocilizumab and infliximab administration.

Authors:  Natalia Maximova; Alessandra Maestro; Davide Zanon; Annalisa Marcuzzi
Journal:  J Immunother Cancer       Date:  2020-02       Impact factor: 13.751

Review 4.  Potentially life‑threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors (Review).

Authors:  Emily L Coleman; Brianna Olamiju; Jonathan S Leventhal
Journal:  Oncol Rep       Date:  2020-12-24       Impact factor: 3.906

Review 5.  Acute Generalized Exanthematous Pustulosis: Pathogenesis, Genetic Background, Clinical Variants and Therapy.

Authors:  Laurence Feldmeyer; Kristine Heidemeyer; Nikhil Yawalkar
Journal:  Int J Mol Sci       Date:  2016-07-27       Impact factor: 5.923

Review 6.  Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies.

Authors:  Chun-Bing Chen; Ming-Ying Wu; Chau Yee Ng; Chun-Wei Lu; Jennifer Wu; Pei-Han Kao; Chan-Keng Yang; Meng-Ting Peng; Chen-Yang Huang; Wen-Cheng Chang; Rosaline Chung-Yee Hui; Chih-Hsun Yang; Shun-Fa Yang; Wen-Hung Chung; Shih-Chi Su
Journal:  Cancer Manag Res       Date:  2018-05-17       Impact factor: 3.989

7.  Piperacillin/Tazobactam-Associated Hypersensitivity Syndrome with Overlapping Features of Acute Generalized Exanthematous Pustulosis and Drug-Related Rash with Eosinophilia and Systemic Symptoms Syndrome.

Authors:  Tae In Kim; Ki Heon Jeong; Min Kyung Shin; Nack In Kim
Journal:  Ann Dermatol       Date:  2016-01-28       Impact factor: 1.444

Review 8.  Drug Triggers and Clinic of Acute Generalized Exanthematous Pustulosis (AGEP): A Literature Case Series of 297 Patients.

Authors:  Enriqueta Vallejo-Yagüe; Adrian Martinez-De la Torre; Omar S Mohamad; Shweta Sabu; Andrea M Burden
Journal:  J Clin Med       Date:  2022-01-13       Impact factor: 4.241
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.